• Anti – coagulation factor
• Anti – hemophilia
• Anti – hemorrhage

• 250 injective units
• 500 injective units

• Effective compound: Coagulation factor VIII extracted from human plasma (500|U_/vial)
• Excipients: glycine, sodium chloride, sodium citrate, calcium chloride, water for injections

• Prevention and treatment of bleeding in hemophilia A (factor 8 congenital deficiency)
• Prevention and treatment of bleeding in factor 8 Acquired deficiency
• Treatment of patients with Factor 8 inhibitors

In case of hypersensitivity to coagulation factor 8 or any of the excipients in the formulation

• Factor 8 solution must administrate through intravenous injection
• Dosage must determine individually based on bleeding causes, the surgery type, severity of factor VIII deficiency and bleeding amount.
• One proposed formulation for Approximate calculation of the required dose is:
• 0/5 × The favorable increase in factor8 (%)× body weight = the required amount

• As with any intravenous injective protein, there is hypersensitive allergic reaction possibility.
• There is possible that body start to produce anti-factor 8 anti-bodies (inhibitors) After continuous frequently treatments with factor 8
• because of possible infectious agents, there is a potential treat of infectious diseases transmission via human blood or plasma. Also, this probability exists about pathogens with unknown nature.
• It’s suggested that patients who receive plasma or blood drive products regularly, vaccinated against hepatitis B (BA).
• The Parvovirus B19 can be a treat for pregnant women (fetal infection) and patients with immunodeficiency or Polycythemia (Like Hemolytic anemia patients)

• Potential allergic reactions in some patients after factor VIII products administration include: Chills, rash and fever
• Headache, tingling, hypotension, severe fatigue, nausea, rapid pulse, feeling of pressure in the chest, irritation and vomiting rarely
• Frequent administration of factor VIII in high dosages can causes Intravascular hemolysis in B, A and AB blood groups due to presence of blood groups isoagglutinins
• Also, in some products high dosages of some products can causes hyperfibrinogenemia. Using other products with higher purity Reduces this risk.
• There is possible that patients with Type A hemophilia produce factor 8 inhibitors, risk potential is higher in first 20 t0 100 administration.
• Low – titer antibodies are mostly temporary and can be overcome with continued treatment with factor 8. But this is not high -titer high responding antibodies in bleeding episodes must control with by passing fraction of factor VIII inhibitors (activated Prothrombin complex concentrate) or activated factor VIIa.

• stored in 25°F
• protect it from light
• protect it from freezing

Molecule of factor 8 consists of two subunits (factor 8 and von willebrand factor) with different physiologic performances. Factor 8 is responsible for coagulation and act as an auxiliary factor with factor 9 in activating factor 10, then activated factor 10 convert Prothrombin to thrombin, thrombin converts fibrinogen into fibrin and clot is formed. In type A hemophilia patients factor 8 activity decrease significantly so alternative treatments are necessary.